Manchester Neuroscience Seminar Series - Assistant Professor Ryota Tamura from Keio University School of Medicine
| Dates: | 3 September 2025 |
|---|
| Times: | 15:00 - 16:00 |
|---|
| What is it: | Seminar |
|---|
| Organiser: | Faculty of Biology, Medicine and Health |
|---|
| Who is it for: | University staff |
|---|
| Speaker: | Ryota Tamura |
|---|
|
Please join the Division of Neuroscience, Wednesday 3 September 2025, for the first Manchester Neuroscience Seminar Series in 25/26, the speaker will be Assistant Professor Ryota Tamura from Keio University School of Medicine.
This seminar will be hosted by Professor Omar Pathmanaban.
When: Wednesday, 3 September 2025 | 15:00 – 16:00
Where: Michael Smith Lecture Theatre
All are welcome
Title: “Development of novel biological treatments for brain tumours”
Abstract: Ryota will talk about translational research including anti-angiogenic immunotherapy for NF2-SWN tumours and stem cell-based gene therapy using iPS cells for malignant glioma.
Research Summary: My clinical and research interests focus on neurosurgical and translational approaches to patients with brain tumors. I am dedicated to management of patients with refractory benign brain tumors including NF2-related schwannomatosis and malignant glioma. As a neurosurgeon, I specialize in skull base techniques for posterior cranial fossa tumors. Active areas of research include anti-angiogenic immunotherapy for the treatment of unresectable benign tumors including NF2-related schwannomatosis. Previously, I led a clinical trial using a vascular endothelial growth factor receptors peptide vaccine in patients with progressive NF2-related schwannomatosis-driven schwannomas returning positive, i.e., hearing improvement and tumor volume reduction. That is the first immunotherapeutic approach for the patients with NF2-related schwannomatosis. Randomized double blind placebo control study is planned in 2025. Another area of my research involves stem cell-based gene therapy using iPS cells for the treatment of malignant glioma and regenerative medicine. I serve as a PI leading multiple preclinical studies evaluating the treatment effect of genome-edited iPS cells utilizing orthotopic immunocompetent glioblastoma models. In 2026, clinical trial using genome-edited iPS cell-derived neural stem cells is planned for the patients with malignant gliomas. These novel treatment strategies may lead to improve the prognosis of patients with refractory benign and malignant brain tumors.
Speaker
Ryota Tamura
Role: Professor
Organisation: Keio University School of Medicine
Travel and Contact Information
Find event
Michael Smith Lecture Theatre
Michael Smith Building
Manchester
